Intracellular delivery of ERBB2 siRNA and p53 gene synergistically inhibits the growth of established tumor in an immunocompetent mouse

Anil Philip Kunnath, Snigdha Tiash, Tahereh Fatemian, Mahboob Morshed, Shar Mariam Mohamed, Md Ezharul Hoque Chowdhury

    Research output: Contribution to journalArticleResearchpeer-review

    9 Citations (Scopus)


    reast cancer is one of the leading causes of deaths worldwide in women with hormone therapy, chemotherapy, targeted therapies, or their combinations being the current options for treating the disease at the different stages (stages I-III) with associated side-effects or increasing life-span at the advanced stage (stage IV). Small interfering RNA (siRNA) as an effective tool to selectively knockdown of a particular gene could be harnessed in combination with plasmid DNA (carrying a gene of interest) and conventional anti-cancer drugs for precisely treating breast cancer with minimal side effects. However the limitation of the naked siRNA and DNA in penetrating the plasma membrane and their sensitiveness to nuclease-mediated cleavage render the technology rather complex in therapeutic intervention. Recently, we have developed pH-sensitive carbonate apatite as a potential nano-carrier to efficiently deliver siRNA or DNA across the cell membrane and facilitate them to escape endosomal acidic compartment resulting in specific cleavage of a particular mRNA transcript or expression of a desirable protein, respectively.
    Original languageEnglish
    Pages (from-to)99 - 104
    Number of pages6
    JournalJournal of Cancer Science & Therapy
    Issue number4
    Publication statusPublished - 2014

    Cite this